Retatrutide & Mots-c

Retatrutide + MOTS-c Quick Start

The retatrutide + MOTS-c stack pairs two research compounds that act on different parts of metabolism. Retatrutide is Eli Lilly's investigational triple-receptor agonist. It acts on GLP-1, GIP, and glucagon receptors to reduce appetite, support insulin response, and raise energy use. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Researchers add it to study how cells use fuel during a retatrutide-driven calorie deficit.

The community calls this combo the Metabolic Super Stack, the Elite Metabolic Stack, or simply reta + MOTS-c. Each name means the same two-compound setup. This page explains the idea behind the stack, its separate-vial schedule, the math for both vials, key risks, and how it compares with other retatrutide stacks.

Format

Separate vials only. There is no commercial pre-blended retatrutide + MOTS-c product.

Schedule

Retatrutide once weekly. MOTS-c 2-3 times weekly or at a low daily dose.

Easy measuring

Both vials use U-100 insulin syringes for typical research doses.

Sequencing

Run retatrutide alone for the first 4 weeks. Add MOTS-c at Week 5 once tolerance is set.

Research status

Reta is in Phase 3. MOTS-c is research-only and banned by WADA.

What Is the Retatrutide + MOTS-c Stack?

The retatrutide + MOTS-c stack is a two-compound metabolic research protocol. Retatrutide acts on appetite, insulin response, and energy use. MOTS-c is added to study fuel use inside the cell. The theory is simple: retatrutide helps create the calorie deficit, while MOTS-c may help mitochondria use the fuel made available during that deficit.

This stack brings together two different areas of research: incretin hormones and mitochondrial function. The closest comparison is the cagrilintide + retatrutide stack, which focuses more on appetite control. The Advanced Recomp Stack adds a growth-hormone secretagogue for more direct lean-mass support.

What Each Compound Does

Retatrutide (LY3437943) is a once-weekly triple agonist. It acts on GLP-1, which reduces appetite and slows stomach emptying; GIP, which affects insulin response; and glucagon, which affects energy use and fat release. In the Phase 3 TRIUMPH-4 trial, the 12 mg group lost 28.7% of body weight at 68 weeks, compared with 2.1% for placebo.

MOTS-c is a 16-amino-acid peptide linked to mitochondria. It activates AMPK, an energy-sensing pathway also affected by exercise and metformin. Much of the proposed benefit comes from cell and animal work. The native peptide has no completed human efficacy trial. The closest human data comes from CB4211, a MOTS-c analog tested in a Phase 1a/1b study.

Why People Pair Them

Retatrutide has produced large weight changes in human trials, but it mainly works through hormone receptors. MOTS-c raises a different question: could it help muscle cells and mitochondria use fuel during the calorie deficit? Here is the idea behind pairing them:

Retatrutide helps release stored fat. MOTS-c may help cells use that fuel through AMPK signaling.

Retatrutide affects insulin response. MOTS-c may help muscles take in glucose through a different pathway.

Early MOTS-c research points to changes in myostatin, a protein tied to muscle growth. This has not been proven in people.

MOTS-c is also linked to some of the signals that rise during exercise. That may matter when a large calorie deficit makes training harder.

Evidence boundary

No human or animal trial has tested retatrutide and MOTS-c together. The pairing above is a theory built from separate studies and community use. It should not be read as proof that the stack works better than retatrutide alone.

Retatrutide + MOTS-c Dosing Protocol & Schedule

Start with the per-compound plan to see how each dose changes. Then use the weekly example to see how the two schedules may fit together. These are research and community patterns, not a tested treatment plan.

Evidence-level notice

No clinical trial has tested retatrutide + MOTS-c together. Retatrutide dosing comes from the Phase 3 TRIUMPH program titration. MOTS-c dosing comes from preclinical work, the CB4211 analog Phase 1 trial, and community practitioner reports.

There is no standard pre-blended retatrutide + MOTS-c vial. The two compounds have different storage limits after mixing, so they are kept in separate vials. Community protocols use subcutaneous injections for both. Neither compound has a supported oral or sublingual form.

For the full standalone schedule, see the retatrutide protocol. For more MOTS-c schedule options, see the MOTS-c dosage guide.

Sequencing - Do Not Start Both on Day One

Community protocols often run retatrutide alone for the first 4 weeks at 1 mg weekly before adding MOTS-c in Week 5. This staged setup makes it easier to track stomach side effects and tell which compound may be causing a new problem. No trial has tested this sequence.

Separate-vial workflow

Independent Dose Control - Two Vials, Two Schedules

Retatrutide is titrated up in 4-week steps. MOTS-c is added at Week 5 with two common approaches: intermittent (most common) or low-dose daily.

Injection burden -                                               Best for -                                                        Cycle driver -

1-2 injections per day on overlap days         Metabolic + mitochondrial pairing           Retatrutide titration sets the pace      

Retatrutide                                    MOTS-c (intermittent - most common)           MOTS-c (low-dose daily -  alternative)                                                                                                                     

Loading                  Frequency                    Loading -                    Frequency -            Loading                          Frequency

1 → 2 → 4              - Once weekly          Start Week 5: 5 mg,         2-3x weekly          Start Week 5                  - Daily

→ 6 → 9 mg                                            2x weekly                                                      : 200 mcg/day, 

(every 4 weeks)                                                                                                +200 mcg every 2 weeks

Maintenance -        Route -                        Maintenance -                Route -                  Maintenance -                  Route -

9 mg or 12 mg         SubQ                          5-10 mg, 2-3x                  SubQ                   Up to 1 mg daily                   SubQ

weekly                                                          weekly                                        

Weekly Schedule Example - Intermittent MOTS-c (Weeks 5-16)

Monday - Retatrutide 2 mg (morning) + MOTS-c 5 mg (pre-training)

Tuesday - Rest day

Wednesday - MOTS-c 5 mg (pre-training)

Thursday - Rest day

Friday - MOTS-c 5 mg (pre-training)

Saturday - Rest day

Sunday - Rest day

Community protocols use different injection sites and separate syringes when both compounds are dosed the same day. Many community protocols dose MOTS-c on Mon/Wed/Fri because it lines up with a typical training split, and MOTS-c is exercise-inducible in animal studies.

Cycle Guidelines

Common Retatrutide + MOTS-c Cycle Approaches

Approach Duration MOTS-c Pattern Best For

Conservative starter Reta weeks 1-24 (titrate to 4-6 mg max) MOTS-c only weeks 5-12, then off First-time stack users, metabolic concerns

Standard research cycle Reta weeks 1-48 (target 9 mg) MOTS-c 8-week pulses with 4-week breaks Most community protocols

Aggressive deficit Reta weeks 1-68 (target 12 mg) MOTS-c 6 weeks on / 2 weeks off, repeating Advanced subjects with established tolerance

Retatrutide is run open-ended in clinical trials (TRIUMPH-4 lasted 68 weeks). Most community protocols pair MOTS-c in pulses inside the reta cycle. Retatrutide is commonly tapered rather than stopped abruptly in community protocols.

There Is No Proven Maintenance Plan

Retatrutide trials have lasted 48-68 weeks. Community plans often run MOTS-c for 4-8 weeks, followed by a break. No study has tested a long-term plan for this stack. A qualified clinician should review any change in dose or decision to stop.

Protocol Notes

Injection sites: Retatrutide is once-weekly so it can take a fixed day. Rotating MOTS-c sites across abdomen, thigh, and flank is a common practice to reduce local irritation.

No oral options: Both compounds are subcutaneous only. Do not try oral or sublingual use.

Why MOTS-c on training days: MOTS-c is exercise-inducible in animal studies, and timing it before training is the most common community pattern. Animal data show enhanced metabolic adaptation when MOTS-c is dosed before exercise.

AMPK stacking caution: MOTS-c activates AMPK. Metformin and berberine also activate AMPK through different paths. Combining them can lower blood glucose more than expected. Test glucose response carefully in the early weeks if you use any of those.

GI tolerance first: Retatrutide TRIUMPH-4 reported nausea in 38.1% (9 mg) and 43.2% (12 mg) of participants. Community protocols avoid raising both compounds at once, stepping retatrutide up first before adding MOTS-c.

Syringe choice: U-100 insulin syringes work for both. Use 0.3 mL syringes with half-unit gradations for retatrutide doses below 1 mg from concentrated vials.

Retatrutide Vials

Once-weekly dosing, titrated upward. A 10 mg vial typically covers 2-5 weeks depending on the dose step.

Cycle length Planning note

16 weeks (titration phase) - 2-3 x 10 mg vials

1 mg → 2 mg → 4 mg → 6 mg → 9 mg across 16 weeks; ~22 mg total used.

24 weeks (conservative cycle) - 3-4 x 10 mg vials

Adds 8 more weekly doses at the maintenance step.

48 weeks (standard cycle) - 6-8 x 10 mg vials

Maintenance at 9 mg weekly drives most of the total.

68 weeks (aggressive)

9-12 x 10 mg vials

Maintenance at 12 mg weekly. Consider 20 mg or 30 mg vials for value.

MOTS-c Vials

Intermittent protocol: 5 mg per injection, 2-3x weekly. MOTS-c is reconstituted-stable for only ~7 days at 2-8 °C, so plan vial sizes around use rate.

Cycle length Planning note

8 weeks MOTS-c pulse

2-3 x 10 mg vials

~16-24 injections of 5 mg; 10 mg vial covers 2 injections.

12 weeks MOTS-c pulse

3-4 x 10 mg vials

~24-36 injections of 5 mg.

Continuous MOTS-c (advanced)

5+ x 10 mg vials per cycle phase

Plan around the 7-day reconstituted window; aliquot or use smaller volumes.

Insulin Syringes (U-100)

Use 0.3 mL / 30-unit syringes for small draws (low-dose reta, low-dose MOTS-c). Use 1 mL syringes for larger volumes.

Cycle length Planning note

16 weeks (reta only first 4 weeks)

~40 syringes

1 reta/week + ~2 MOTS-c/week from Week 5 onward.

24 weeks

~60 syringes

1 reta/week + intermittent MOTS-c pulses.

48 weeks

~120 syringes

Buy in bulk; 1 syringe per injection.

Bacteriostatic Water

Each compound is reconstituted separately. Plan around MOTS-c's shorter reconstituted window.

Cycle length Planning note

16 weeks

1-2 x 10 mL bottles

~3-6 mL used across reta + MOTS-c reconstitutions.

24 weeks

2 x 10 mL bottles

Two bottles give margin for re-reconstituting MOTS-c.

48 weeks

3-4 x 10 mL bottles

MOTS-c is reconstituted multiple times across the cycle.

Retatrutide + MOTS-c Dosage Chart

Retatrutide + MOTS-c Reconstitution Guide

Each compound is mixed on its own. I cross-checked the tables against the Retatrutide protocol page and MOTS-c protocol page so the dose math stays consistent across the site.

Label every vial

Both compounds use U-100 insulin syringes. A draw error matters - 0.2 mL at retatrutide 10 mg/mL is 2 mg of retatrutide. The same volume at MOTS-c 10 mg/mL is 2 mg of MOTS-c. Concentration changes everything. Label each vial with the compound name, concentration, and date.

Retatrutide Reconstitution Math

For more vial sizes and the full standalone guide, see the retatrutide protocol.

Retatrutide - mg per dose at common vial sizes

Vial Size BAC Water Concentration 2 mg Dose 4 mg Dose 6 mg Dose 9 mg Dose

5 mg 1.0 mL 5 mg/mL

0.40 mL (40 units)

0.80 mL (80 units)

N/A N/A

10 mg 1.0 mL 10 mg/mL

0.20 mL (20 units)

0.40 mL (40 units)

0.60 mL (60 units)

0.90 mL (90 units)

10 mg 2.0 mL 5 mg/mL

0.40 mL (40 units)

0.80 mL (80 units)

1.20 mL (120 units*)

1.80 mL (180 units*)

20 mg 2.0 mL 10 mg/mL

0.20 mL (20 units)

0.40 mL (40 units)

0.60 mL (60 units)

0.90 mL (90 units)

30 mg 3.0 mL 10 mg/mL

0.20 mL (20 units)

0.40 mL (40 units)

0.60 mL (60 units)

0.90 mL (90 units)

* Volume above 100 units exceeds a standard 1 mL insulin syringe - split into two injections or use a larger syringe.

MOTS-c Reconstitution Math

For more vial sizes and calculations, see the MOTS-c dosage guide.

MOTS-c - common doses at common vial sizes

Vial Size BAC Water Concentration 5 mg Dose 2.5 mg Dose 1 mg Dose 200 mcg Dose

5 mg 1.0 mL 5 mg/mL

1.0 mL (100 units)

0.50 mL (50 units)

0.20 mL (20 units)

0.04 mL (4 units)

5 mg 2.0 mL 2.5 mg/mL

2.0 mL (200 units*)

1.0 mL (100 units)

0.40 mL (40 units)

0.08 mL (8 units)

10 mg 1.0 mL 10 mg/mL

0.50 mL (50 units)

0.25 mL (25 units)

0.10 mL (10 units)

0.02 mL (2 units)

10 mg 2.0 mL 5 mg/mL

1.0 mL (100 units)

0.50 mL (50 units)

0.20 mL (20 units)

0.04 mL (4 units)

10 mg 3.0 mL 3.33 mg/mL

1.50 mL (150 units*)

0.75 mL (75 units)

0.30 mL (30 units)

0.06 mL (6 units)

* Volumes above 100 units exceed a standard 1 mL insulin syringe.

Plan around MOTS-c's 7-day window

MOTS-c is reconstituted-stable for about 7 days at 2-8 °C before potency starts to drop. Retatrutide holds for 28-60 days at 2-8 °C. Reconstitute MOTS-c in smaller volumes you can use within a week, or aliquot the reconstituted vial into freezer-safe containers for -20 °C storage (2-3 months).

Why Add MOTS-c to a Retatrutide Protocol?

Retatrutide does most of the work on appetite, insulin response, and energy use. MOTS-c is added to study how cells use fuel during a large calorie deficit. I reviewed the main research on both compounds before breaking down the four possible links below. These links may explain why people pair them, but the stack itself has never been tested.

What Retatrutide Already Provides

Retatrutide reduces appetite through GLP-1, affects insulin response through GIP, and raises energy use through glucagon. This can create a large calorie deficit, which may also bring fatigue and lean-mass loss. MOTS-c does not replace protein or resistance training. Researchers add it to study whether its effects on mitochondria and muscle could offer extra support.

Pathway 1 - Mitochondrial Fat Oxidation (AMPK)

MOTS-c activates AMP-activated protein kinase (AMPK), an energy sensor that helps cells change how they use fuel. Retatrutide affects appetite, energy use, and fat release. Researchers pair them in hopes that MOTS-c will help cells use the fuel made available during that process. No trial has shown that adding MOTS-c leads to more fat loss.

Pathway 2 - Insulin Sensitivity at Two Layers

The compounds may affect glucose control at different points. Retatrutide acts on the GIP receptor, which affects insulin response. MOTS-c has improved glucose uptake into skeletal muscle in animal models. This possible overlap is one reason people pair them. It is also why low blood sugar is a concern when other glucose-lowering drugs or supplements are used.

Pathway 3 - Lean Mass Through Myostatin

Early MOTS-c studies suggest that it may lower myostatin signaling. Myostatin is a protein that limits muscle growth. This could matter when trying to keep muscle during a calorie deficit, but it remains the least proven reason for using the stack. There is no direct human evidence.

Pathway 4 - Exercise-Mimetic Signaling

MOTS-c is linked to some of the same signals that rise with exercise. In one animal study, old mice given MOTS-c roughly doubled their treadmill time. This does not prove the same result in people. It explains why many community plans place MOTS-c on training days, when fatigue from a calorie deficit may be most noticeable.

When Researchers Consider the Stack

Retatrutide alone produced 28.7% average weight loss at the top dose in TRIUMPH-4. MOTS-c is not needed to show that retatrutide can drive weight loss. Researchers consider the stack when the question is about mitochondrial function, fatigue, or lean mass during the deficit. Whether MOTS-c improves any of those outcomes in people remains unknown.

Reminder

The pathways above come from separate compound studies. No published human or animal trial has measured outcomes for retatrutide + MOTS-c as a stack. The possible synergy is based on mechanism, not direct proof.

Retatrutide + MOTS-c Side Effects and Interaction Risks

No clinical study has measured the side effects of retatrutide and MOTS-c when used together. Retatrutide has documented stomach and appetite-related effects in clinical trials, while human safety data for native MOTS-c remains limited. Combining them may create risks that cannot be predicted from separate-compound studies.

Side Effects Reported in Retatrutide Trials

Published trial finding: nausea. In TRIUMPH-4, nausea affected 38.1% of the 9 mg group and 43.2% of the 12 mg group.

Published trial finding: stopping treatment. Discontinuation rates were 12.2% to 18.2% across the 9 mg and 12 mg groups.

Published trial finding: unusual skin feelings. Tingling and similar feelings were reported in 8.8% of the 9 mg group and 20.9% of the 12 mg group, compared with 0.7% on placebo.

Other stomach effects reported with retatrutide include diarrhea, constipation, and vomiting.

What Is Known About MOTS-c Side Effects

Human safety data for native MOTS-c is limited. Most findings come from animal studies, while the related analog CB4211 reached a Phase 1 trial. Community users report short-term injection-site redness, fatigue, lightheadedness, and sleep changes. These reports are not clinical evidence and cannot show how often an effect occurs.

Possible Overlapping Concerns

Low blood sugar. Retatrutide affects insulin response, while MOTS-c affects AMPK and muscle glucose uptake. The possible overlap may matter more during fasted training or with metformin, berberine, insulin, or other glucose-lowering products.

Several AMPK activators at once. MOTS-c, metformin, and berberine affect AMPK through different paths. Their combined effect in people is not well defined.

More injection reactions. Using two injected compounds means more injection sites and more chances for redness or irritation.

Product quality and handling. Two research vials create two chances for contamination, a label error, or weak material. Check a current, batch-matched third-party COA for both compounds. See the PepPal guide to reading COAs.

What Has Not Been Studied

No study has measured whether MOTS-c changes retatrutide side effects, whether the pair creates new risks, or how either compound affects the other's action. The risk from long-term combined use is also unknown. Medical review is especially important for anyone with severe stomach disease, type 1 diabetes, a history of pancreatitis, a personal or family history of medullary thyroid cancer, active cancer, or medicines that lower blood sugar.

When to reassess

If GI symptoms worsen instead of improving over the first 2-3 weeks, if any unusual symptom appears, or if blood glucose readings drop more than expected, pause and consult a qualified clinician.